Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (NYSE American: MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: April 2, 2026
Event: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard.
Key Financial Metrics
The filing provides limited financial data, focusing on equity status relative to listing standards:
- Stockholders' Equity: $4.83 million as of December 31, 2025.
- Profitability Status: The Company has reported losses from continuing operations and/or net losses in each of its five most recent fiscal years ended December 31, 2025.
- Revenue, Cash Flow, and Debt: The filing text does not provide specific values for revenue, operating cash flow, or debt levels.
Material Changes and Listing Compliance
On April 2, 2026, the Company received a written notice from NYSE American indicating non-compliance with continued listing standards under Section 1003(a) of the Company Guide. Specifically:
- The Company failed to meet the requirement of maintaining at least $6.0 million in stockholders' equity due to reporting losses in its five most recent fiscal years.
- Current equity of $4.83 million falls below the $6.0 million threshold required for companies with five consecutive years of losses.
- The Company is not currently eligible for any exemptions under Section 1003(a).
Outlook, Management Commentary, and Risks
Compliance Plan and Timeline:
- The Company must submit a plan of action to regain compliance by May 2, 2026.
- If the plan is accepted, the Company may be granted up to 18 months (the "Cure Period") to regain compliance.
- During the Cure Period, the Company will be subject to quarterly monitoring.
Risks and Contingencies:
- There is no assurance the Company will achieve compliance within the Cure Period.
- If the plan is not accepted, delisting proceedings will commence.
- The Company may appeal a staff delisting determination.
- Immediate Impact: The notice has no immediate impact on the listing or trading of shares, and ongoing business operations and SEC reporting requirements remain unaffected.
Investor Verification Checklist
- Verify the submission of the compliance plan by the May 2, 2026 deadline.
- Monitor the NYSE American's acceptance or rejection of the proposed plan.
- Review the Company's 2025 Annual Report (Form 10-K) for detailed financial statements regarding revenue, cash burn, and debt.
- Assess the feasibility of the Company's strategy to increase stockholders' equity within the 18-month Cure Period.
- Watch for any subsequent filings regarding the appeal process if the plan is rejected.